Hynes NE - Search Results

1

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

Motoyama AB, Hynes NE, Lane HA. Motoyama AB, et al. Among authors: hynes ne. Cancer Res. 2002 Jun 1;62(11):3151-8. Cancer Res. 2002. PMID: 12036928

2

BAD: a good therapeutic target?

Motoyama AB, Hynes NE. Motoyama AB, et al. Among authors: hynes ne. Breast Cancer Res. 2003;5(1):27-30. doi: 10.1186/bcr552. Epub 2002 Oct 18. Breast Cancer Res. 2003. PMID: 12559042 Free PMC article.

3

ERBB receptors and cancer: the complexity of targeted inhibitors.

Hynes NE, Lane HA. Hynes NE, et al. Nat Rev Cancer. 2005 May;5(5):341-54. doi: 10.1038/nrc1609. Nat Rev Cancer. 2005. PMID: 15864276 Review.

4

The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.

Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, Wartmann M, Stumm M, Lane HA, Hynes NE. Boulay A, et al. Among authors: hynes ne. Cancer Res. 2008 May 15;68(10):3743-51. doi: 10.1158/0008-5472.CAN-07-5100. Cancer Res. 2008. PMID: 18483257

5

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency.

Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. Lane HA, et al. Among authors: hynes ne. Mol Cell Biol. 2000 May;20(9):3210-23. doi: 10.1128/MCB.20.9.3210-3223.2000. Mol Cell Biol. 2000. PMID: 10757805 Free PMC article.

6

The ErbB signaling network: receptor heterodimerization in development and cancer.

Olayioye MA, Neve RM, Lane HA, Hynes NE. Olayioye MA, et al. Among authors: hynes ne. EMBO J. 2000 Jul 3;19(13):3159-67. doi: 10.1093/emboj/19.13.3159. EMBO J. 2000. PMID: 10880430 Free PMC article. Review. No abstract available.

7

Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase.

Hynes NE, Lane HA. Hynes NE, et al. J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):141-50. doi: 10.1023/a:1009528918064. J Mammary Gland Biol Neoplasia. 2001. PMID: 11467449 Review.

8

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.

Lane HA, Motoyama AB, Beuvink I, Hynes NE. Lane HA, et al. Among authors: hynes ne. Ann Oncol. 2001;12 Suppl 1:S21-2. doi: 10.1093/annonc/12.suppl_1.s21. Ann Oncol. 2001. PMID: 11521716 Free article. Review.

9

The role of overexpressed HER2 in transformation.

Neve RM, Lane HA, Hynes NE. Neve RM, et al. Among authors: hynes ne. Ann Oncol. 2001;12 Suppl 1:S9-13. doi: 10.1093/annonc/12.suppl_1.s9. Ann Oncol. 2001. PMID: 11521729 Free article. Review.

10

NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.

Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, Hynes NE. Daly JM, et al. Among authors: hynes ne. Oncogene. 1999 Jun 10;18(23):3440-51. doi: 10.1038/sj.onc.1202700. Oncogene. 1999. PMID: 10376522

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

224 results

Search Page

Filters